<DOC>
	<DOCNO>NCT01111058</DOCNO>
	<brief_summary>Primary : Two-year progression-free ( tumor grow spread ) survival subject treat everolimus versus placebo definitive local therapy .</brief_summary>
	<brief_title>Everolimus Versus Placebo Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis Squamous cell carcinoma head neck ( stage IVa IVb ) . No evidence ( absence ) disease scan . 18 year old . Performance status 70 % good . Adequate marrow , renal liver function ( tested lab ) . _ Able give consent . Currently receive anticancer treatment . Major surgery traumatic injury within 4 week . Radiotherapy related toxicity . Lip , nasopharynx , nasal cavity , paranasal sinus , salivary gland , skin , thyroid primary tumor Receiving investigational drug . Receiving chronic , systemic treatment corticosteroid another immunosuppressive agent . Receive immunization attenuate live vaccine ( seasonal flu shot ) 1 week start . Show evidence disease ( cancer ) . Uncontrolled medical condition : unstable angina , congestive heart failure , diabetes , severely impaired lung function . Liver disease cirrhosis , severe hepatic impairment , Hepatitis B C. Active , uncontrolled severe infection Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . Known History HIV positivity . Impaired gastrointestinal function may alter absorption Everolimus ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection . Patients active , bleeding diathesis . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . ) Male patient whose sexual partner ( ) Women child bear potential willing use adequate . contraception , study 8 week end treatment Patients receive prior treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . Patients know hypersensitivity Everolimus rapamycin analogue ( sirolimus , temsirolimus ) excipients . History noncompliance medical regimen . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Squamous Cell Cancer</keyword>
</DOC>